H
Hyku Biosciences
Precise covalent targeting of disease-causing proteins and developing small molecule therapeutics with novel mechanisms of action to transform conventional treatment paradigms
About Hyku Biosciences
Hyku Biosciences is at the forefront of developing small molecule therapeutics designed to inactivate proteins that drive disease progression. Operating in the biopharmaceutical sector, Hyku focuses on pioneering covalent medicines that target histidine, tyrosine, and lysine binding pockets within disease-causing proteins. This approach offers superior selectivity and drug properties by irreversibly blocking the activity of these targets, expanding beyond the traditional cysteine targeting methods.
The company serves patients suffering from diseases driven by these proteins, aiming to transform conventional treatment paradigms. Hyku's business model revolves around research and development of these novel therapeutics, with revenue generated through partnerships, licensing agreements, and potentially direct sales of approved drugs.
Hyku Biosciences is committed to innovation, collaboration, and respect within its diverse team, all united by the mission to improve patient lives.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEEDOther financing | Sep 2023 | $56M | $224M | KB Investment · RA Capital Management · Droia Oncology Ventures · The Mark Foundation for Cancer Research | ↗ |
| SPINOUTOther financing | Jan 2019 | $0 | — | University of Virginia | — |
Growth signals
Latest recorded traffic for Hyku Biosciences is 1K monthly website visits, down 33.3% over the last three months. Hyku Biosciences's team declined 25% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hyku Biosciences in the Burlington ecosystem
The Hyku Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
RA Capital Management
Droia Oncology Ventures
Novartis Venture Fund
KB Investment
The Mark Foundation for Cancer Research
Eisai Innovation
Other known investors1 additional known investor
University of Virginia
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hyku Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hyku Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










